While these immunotherapies have shown efficacy in treating specific cancers, their utility is limited by the fact that their effectiveness is predominantly confined to cancer types with insufficient and heterogeneous expression of PD-1 in the tumor microenvironment. The gene discussed is PDCD1; the disease is neoplasm.